Table 1.
Followed Cohort |
Lost to follow-up |
P-Value |
|||||||
---|---|---|---|---|---|---|---|---|---|
Groupa | N | n | Age (year) | Male (%) | n | Age (year) | Male (%) | Age | Male |
Group I | 241 | 104 | 31.35 ± 7.90 | 44 (42.3) | 137 | 32.06 ± 7.90 | 53 (38.7) | 0.508 | 0.570 |
Group II | 290 | 45 | 32.35 ± 8.15 | 13 (28.9) | 245 | 32.35 ± 8.34 | 106 (43.3) | 0.998 | 0.072 |
Group III | 240 | 93 | 34.15 ± 8.20 | 30 (32.3) | 147 | 32.65 ± 8.23 | 66 (44.9) | 0.168 | 0.051 |
Total | 771 | 242 | 32.62 ± 8.15 | 87 (36.0) | 529 | 32.36 ± 8.32 | 225 (42.5) | 0.691 | 0.084 |
Parameter | F = 2.978b | χ2 = 3.351c | F = 0.175b | χ2 = 1.220c | |||||
P value | P = .053 | P = .190 | P = .840 | P = .543 |
aParticipants were assigned to one of the three groups depending on the vaccination schedule chosen. Group I: vaccinated at 0–1–3 months; group II: vaccinated at 0–1–6 months; group III: vaccinated at 0–1–12 months.
bThe variance analysis was used to compare age among the three groups.
cThe Pearson chi-square test was used to compare sex among the three groups.